"The market share of biosimilars can be greatly improved," said Dr. José Antonio Marcos, a Hospital Pharmacy professional at Hospital Virgen Macarena (Seville), who in a way opted to increase said share taking into account the savings associated with the use of this type of drugs, since biosimilars allow treating a “greater number of patients with the same budget”. Marcos participated in the webinar '6 practical questions about... Biosimilars in oncology: a new form of innovation in cancer', answering three of those six questions, while the other three were answered by Dr. Joan Albanell, head of the Medical Oncology Service of the Hospital del Mar (Barcelona). Dr. Ruth Vera, head of the Medical Oncology Service of the Hospital Complex of Navarra, moderated the session, which was closed by Dr. Carlos Camps, head of the Medical Oncology Service of the General Hospital of Valencia. The webinar, organized by the ECO Foundation (Foundation for Excellence and Quality in Oncology), was sponsored by Pfizer and scientifically endorsed by the Spanish Society of Medical Oncology (SEOM).